Waters and University of Delaware Announce Official Opening of Immerse Delaware Lab
News Summary:
- Waters opens its newest innovation and research laboratory at University of Delaware (UD) Science, Technology and Advanced Research (STAR) campus
- Immerse™ Delaware brings together students, faculty, and Waters scientists with industry research partners to identify and address significant challenges facing the biopharmaceutical industry
- Lab opening milestone is part of multi-year Waters-UD research partnership to collaborate on projects with biopharma industry stakeholders
Excerpt from the Press Release:
MILFORD, Mass. & NEWARK, Del.–(BUSINESS WIRE)–Waters Corporation (NYSE: WAT) and The University of Delaware announced the grand opening of Immerse™ Delaware, a new Waters innovation and research laboratory. As part of their multi-year research partnership announced in October 2021, the lab opening is the first step on a journey to collaborate with biopharma scientists both in industry and academia to advance industrial processes for making and characterizing biotherapeutics.
Located at the University of Delaware Science, Technology and Advanced Research (STAR) campus, Immerse Delaware is a fully functional, fit-for-purpose, bioprocess laboratory enabling a dedicated focus on the entire manufacturing process from clone selection to quality control (QC) of drug substances. It will give students, faculty and industry researchers access to use and evaluate state-of-the-art analytical technologies from Waters as well as novel analytics, consumables and software that will enable the next generation of biotherapeutics.
“Our mission to address some of the biggest challenges in the development and manufacturing of biotherapeutics requires an immense amount of work, collaboration, and diversity of thought. Immerse Delaware will enable us to tap into an ecosystem of talent and expertise in biological manufacturing, coupled with Waters’ experience in analytical technologies, to advance and accelerate the delivery of high-quality medicines to patients,” said Dr. Udit Batra, President and CEO of Waters Corporation.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?